



COVID Codes

CPT Code or HCPCS Code	CPT or HCPCS Short Descriptor	Vaccine/Procedure Name	Effective Dates
91300	SARSCOV2 VAC 30MCG/0.3ML IM	Pfizer-BioNTech Covid-19 Vaccine	12/11/2020 – TBD
0001A	ADM SARSCOV2 30MCG/0.3ML 1ST	Pfizer-BioNTech Covid-19 Vaccine Administration – First Dose	12/11/2020 – TBD
0002A	ADM SARSCOV2 30MCG/0.3ML 2ND	Pfizer-BioNTech Covid-19 Vaccine Administration – Second Dose	12/11/2020 – TBD
0003A	ADM SARSCOV2 30MCG/0.3ML 3RD	Pfizer-BioNTech Covid-19 Vaccine Administration – Third Dose	08/12/2021 – TBD
0004A	ADM SARSCOV2 30MCG/0.3ML BST	Pfizer-BioNTech Covid-19 Vaccine Administration – Booster	09/22/2021 – TBD
91301	SARSCOV2 VAC 100MCG/0.5ML IM	Moderna Covid-19 Vaccine	12/18/2020 – TBD
0011A	ADM SARSCOV2 100MCG/0.5ML1ST	Moderna Covid-19 Vaccine Administration – First Dose	12/18/2020 – TBD
0012A	ADM SARSCOV2 100MCG/0.5ML2ND	Moderna Covid-19 Vaccine Administration – Second Dose	12/18/2020 – TBD
0013A	ADM SARSCOV2 100MCG/0.5ML3RD	Moderna Covid-19 Vaccine Administration – Third Dose	08/12/2021 – TBD
91303	SARSCOV2 VAC AD26 .5ML IM	Janssen Covid-19 Vaccine[3]***	02/27/2021 – TBD
0031A	ADM SARSCOV2 VAC AD26 .5ML	Janssen Covid-19 Vaccine Administration - First Dose[3]***	02/27/2021 – TBD
0034A	ADM SARSCOV2 VAC AD26 .5ML B	Janssen Covid-19 Vaccine Administration - Booster[3]***	10/20/2021 – TBD
91306	SARSCOV2 VAC 50MCG/0.25ML IM	Moderna Covid-19 Vaccine (Low Dose)	10/20/2021 – TBD
0064A	ADM SARSCOV2 50MCG/0.25MLBST	Moderna Covid-19 Vaccine (Low Dose) Administration - Booster	10/20/2021 – TBD
91307	SARSCOV2 VAC 10 MCG TRS-SUCR	Pfizer-BioNTech Covid-19 Pediatric Vaccine	10/29/2021 - TBD
0071A	ADM SARSCV2 10MCG TRS-SUCR 1	Pfizer-BioNTech Covid-19 Pediatric Vaccine - Administration - First dose	10/29/2021 - TBD
0072A	ADM SARSCV2 10MCG TRS-SUCR 2	Pfizer-BioNTech Covid-19 Pediatric Vaccine - Administration - Second dose	10/29/2021 - TBD
0073A	ADM SARSCV2 10MCG TRS-SUCR 3	Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) - Administration - Third dose	01/03/2022 - TBD
M0201	Covid-19 vaccine home admin	Covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home	06/08/2021 - TBD
Q0239	Bamlanivimab-xxxx	Injection, bamlanivimab, 700 mg	11/10/2020 – 04/16/2021[4]
M0239	Bamlanivimab-xxxx infusion	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	11/10/2020 – 04/16/2021[4]
Q0240[6]	Casirivi and imdevi 600mg	Injection, casirivimab and imdevimab, 600 mg	07/30/2021 – TBD



M0240[6]	Casiri and imdev repeat	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses	07/30/2021 – TBD
M0241[6]	Casiri and imdev repeat hm	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses	07/30/2021 – TBD
Q0243	Casirivimab and imdevimab	Injection, casirivimab and imdevimab, 2400 mg	11/21/2020 – TBD
Q0244[5]	Casirivi and imdevi 1200 mg	Injection, casirivimab and imdevimab, 1200 mg	06/03/2021 – TBD
M0243	Casirivi and imdevi inj	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	11/21/2020 – TBD
M0244	Casirivi and imdevi inj hm	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	05/06/2021 – TBD
Q0245	Bamlanivimab and etesevima	Injection, bamlanivimab and etesevimab, 2100 mg	02/09/2021 – TBD
M0245	Bamlan and etesev infusion	intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	02/09/2021 – TBD
M0246	Bamlan and etesev infus home	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	05/06/2021 – TBD
Q0247[7]	Sotrovimab	Injection, sotrovimab, 500 mg	05/26/2021 – TBD
M0247	Sotrovimab infusion	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	05/26/2021 – TBD
M0248	Sotrovimab inf, home admin	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	05/26/2021 – TBD
Q0249	Tocilizumab for COVID-19	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	06/24/2021 - TBA
M0249	Adm Tocilizu COVID-19 1st	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen,	06/24/2021 - TBA



		non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose	
M0250	Adm Tocilizu COVID-19 2nd	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose	06/24/2021 - TBA
Q0220	Tixagev and cilgav, 300mg	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg	12/08/2021 - TBD
M0220	Tixagev and cilgav inj	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	
M0221	Tixagev and cilgav inj hm	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	12/08/2021 - TBD